TY - JOUR
T1 - Implementation strategies for the first licensed dengue vaccine
T2 - A meeting report
AU - Fongwen, Noah
AU - Delrieu, Isabelle
AU - Ham, Leong Hoe
AU - Gubler, Duane J.
AU - Durbin, Anna
AU - Ooi, Eng Eong
AU - Peeling, Rosanna W.
AU - Flasche, Stefan
AU - Hartigan-Go, Kenneth
AU - Clifford, Sam
AU - Martinez, Carlos Torres
AU - de Lamballerie, Xavier
AU - Barnighausen, Till
AU - Wilder-Smith, Annelies
N1 - Funding Information:
The meeting was funded through The Partnership for Dengue Control that has received unrestricted funds by Sanofi Pasteur, Takeda and the Bill&Melinda Gates Foundation.
Publisher Copyright:
© 2021
PY - 2021/8/9
Y1 - 2021/8/9
N2 - Dengue vaccination would enhance the control of dengue, one of the most frequent vector-borne viral diseases globally. CYD-TDV is the first dengue vaccine to be licensed, but global uptake has been hampered due to its use being limited to seropositive persons aged 9 years and above, and the need for a 3-dose schedule. The Partnership for Dengue Control (PDC) organized a meeting with key opinion leaders and stakeholders to deliberate on implementation strategies for the use of CYD-TDV. New data have emerged that support the shortening of the primary schedule from a 3 to 2 dose schedule, extending the age range below 9 to 6 years of age, and expanding the indication from endemic populations to also include travelers to endemic areas. Cost-effectiveness may improve with the modified 2-dose regimen and with multiple testing. Strategies to implement a dengue vaccination program have been developed, in particular school-based strategies. A range of delivery scenarios can then be considered, using various settings for each step of the intervention. However, several challenges remain, including communication about limiting the use of this vaccine to seropositive individuals only. Affordability will vary from country to country, as will government commitment and community acceptance. Well-tailored communication strategies that target key stakeholders are expected to make up a significant part of any future dengue vaccination program.
AB - Dengue vaccination would enhance the control of dengue, one of the most frequent vector-borne viral diseases globally. CYD-TDV is the first dengue vaccine to be licensed, but global uptake has been hampered due to its use being limited to seropositive persons aged 9 years and above, and the need for a 3-dose schedule. The Partnership for Dengue Control (PDC) organized a meeting with key opinion leaders and stakeholders to deliberate on implementation strategies for the use of CYD-TDV. New data have emerged that support the shortening of the primary schedule from a 3 to 2 dose schedule, extending the age range below 9 to 6 years of age, and expanding the indication from endemic populations to also include travelers to endemic areas. Cost-effectiveness may improve with the modified 2-dose regimen and with multiple testing. Strategies to implement a dengue vaccination program have been developed, in particular school-based strategies. A range of delivery scenarios can then be considered, using various settings for each step of the intervention. However, several challenges remain, including communication about limiting the use of this vaccine to seropositive individuals only. Affordability will vary from country to country, as will government commitment and community acceptance. Well-tailored communication strategies that target key stakeholders are expected to make up a significant part of any future dengue vaccination program.
KW - CYD-TDV
KW - Dengue vaccine
KW - Dengvaxia
KW - Label change
KW - Rapid diagnostic tests
KW - Screening
KW - Serostatus
KW - Test and vaccinate
UR - http://www.scopus.com/inward/record.url?scp=85110482001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110482001&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2021.06.083
DO - 10.1016/j.vaccine.2021.06.083
M3 - Article
C2 - 34253416
AN - SCOPUS:85110482001
VL - 39
SP - 4759
EP - 4765
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 34
ER -